CXCR4:肾上腺皮质癌的潜在新型诊疗靶点
本文报道一例局部复发伴腹膜转移的肾上腺皮质癌患者,FDG与68Ga-pentixafor PET/CT均清晰显示病灶,提示CXCR4高表达为转移性肾上腺皮质癌的诊疗一体化及靶向内照射治疗提供可能,并观察到胸腺反弹表现为68Ga-pentixafor轻至中度摄取。
要点
- 肾上腺皮质癌侵袭性强、复发率高、预后差,治疗选择有限且应答率低。
- 肾上腺皮质癌可表达趋化因子受体CXCR4,可用68Ga-pentixafor PET/CT显像。
- 本例局部复发伴腹膜转移灶在FDG与pentixafor PET/CT上均清晰显示。
核心结论
- CXCR4高表达为转移性肾上腺皮质癌患者提供了诊疗一体化及靶向内照射治疗的潜在可能。
研究设计与样本
- 本文为病例报告,报道一例局部复发伴腹膜转移的肾上腺皮质癌患者。
主要发现
- 该例肾上腺皮质癌的局部复发和腹膜转移灶在FDG与68Ga-pentixafor PET/CT上均清晰显示。
- 该患者中观察到胸腺反弹,表现为68Ga-pentixafor轻至中度摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adrenocortical carcinoma (ACC) is a highly aggressive malignancy with high recurrence rates and poor prognosis. There are only limited treatment options with poor response rates. ACCs are documented to express chemokine receptor CXCR4, which can be visualized using 68 Ga-pentixafor PET/CT. We herein present a case of ACC with local recurrence and peritoneal metastases, which was well visualized on FDG and pentixafor PET/CT. The high expression of CXCR4 offers the potential of theranostics and targeted endoradiotherapy in patients with metastatic ACC. We also observed thymic rebound to illustrate mild to moderate grade uptake of 68 Ga-pentixafor in this patient.
引用
- Nazar A, Kalshetty A, Basu S, et al. CXCR4-A Potential Novel Theranostic Target in Adrenocortical Carcinoma. Clin Nucl Med. 2024. PMID: 40042244. doi:10.1097/RLU.0000000000005656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。